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Abstract: Phylloseptin (PS) peptides, derived from South American hylid frogs (subfamily
Phyllomedusinae), have been found to have broad-spectrum antimicrobial activities and relatively
low haemolytic activities. Although PS peptides have been identified from several well-known and
widely-distributed species of the Phyllomedusinae, there remains merit in their study in additional,
more obscure and specialised members of this taxon. Here, we report the discovery of two novel
PS peptides, named PS-Du and PS-Co, which were respectively identified for the first time and
isolated from the skin secretions of Phyllomedusa duellmani and Phyllomedusa coelestis. Their encoding
cDNAs were cloned, from which it was possible to deduce the entire primary structures of their
biosynthetic precursors. Reversed-phase high-performance liquid chromatography (RP-HPLC) and
tandem mass spectrometry (MS/MS) analyses were employed to isolate and structurally-characterise
respective encoded PS peptides from skin secretions. The peptides had molecular masses of 2049.7 Da
(PS-Du) and 1972.8 Da (PS-Co). They shared typical N-terminal sequences and C-terminal amidation
with other known phylloseptins. The two peptides exhibited growth inhibitory activity against
E. coli (NCTC 10418), as a standard Gram-negative bacterium, S. aureus (NCTC 10788), as a standard
Gram-positive bacterium and C. albicans (NCPF 1467), as a standard pathogenic yeast, all as planktonic
cultures. Moreover, both peptides demonstrated the capability of eliminating S. aureus biofilm.
Keywords: amphibian; phylloseptin; antimicrobial; peptide; biofilm; membrane permeability
1. Introduction
Amphibians possess a special innate skin defence system to protect them from being preyed
upon by predators and infected by microorganisms in their living environments. So far, hundreds of
antimicrobial peptides have been discovered in amphibian skins and these have been widely-studied
in recent decades [1–4]. These amphibian antimicrobial peptides have been divided into different
families according to structural similarities and these include the brevinins, esculentins, temporins,
dermaseptins, phylloseptins and bombinins [5–8]. Peptides within a certain family can inhibit the
growth of selected bacteria and fungi and some may also possess anti-cancer and/or anti-viral
activities [9–11].
Phyllomedusa is a genus of leaf frogs within the hylid frog subfamily, Phyllomedusinae [12].
So far, more than 80 antimicrobial peptides have been discovered from the skin secretions of species
within this subfamily and these peptides have been divided into seven peptide families including
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the dermaseptins, phylloseptins (PS), plasticins, dermatoxins, phylloxins, hyposins, and orphan
peptides [13]. The prototype of the phylloseptin (PS) family, was first reported in 2005 [14]. In the past
decade, more than 40 novel PS peptides have been identified and all demonstrate a broad-spectrum of
antimicrobial activities, especially significantly inhibiting the growth of Gram-positive bacteria and
fungi [14–19].
Phyllomedusa duellmani and Phyllomedusa coelestis are members of genus Phyllomedusa. Unlike their
relatives, Phyllomedusa hypochondrialis, Phyllomedusa sauvagei and other species, which have been widely
studied, only a few bioactive peptides have been reported from these two species. These two species
are found in northern Peru and the population status of Phyllomedusa duellmani is still shown as data
deficient on the Red List of Endangered Species [20].
In this study, “shotgun” cloning was performed using both 3′RACE and 5′RACE polymerase
chain reaction (PCR)to obtain full-length nucleotide sequences encoding the open reading frames of
their respective PS biosynthetic precursors. The amino acid sequences of predicted PS peptides were
confirmed by tandem mass spectrometry (MS/MS) fragmentation using electrospray ion trap mass
spectrometry. After chemical synthesis of replicates of both peptides, their biological activities were
investigated in antimicrobial and haemolysis bioassays.
2. Results
2.1. “Shotgun” Cloning of Novel Peptide Precursor-Encoding cDNAs and Bioinformatic Analyses
Degenerate primers were used for interrogating the skin secretion-derived cDNA libraries of
Phyllomedusa duellmani and Phyllomedusa coelestis. Two full-length cDNAs, encoding PS-Du and PS-Co,
were cloned repeatedly (at least 10 clones for each) from the skin secretion-derived cDNA libraries of
Phyllomedusa duellmani and Phyllomedusa coelestis, respectively. They were named PS-Du and PS-Co,
respectively, reflecting their species names. The sequences of nucleotides and translated open reading
frame amino acids for both peptides are shown in Figure 1A, B. Their structural topology consisted of
five typical regions, including a putative signal peptide region of 22 amino acid residues, an acidic
“spacer” peptide, typical -KR- propeptide convertase processing sites, a mature peptide of 19 amino
acid residues and a Gly residue at the C-terminus which acts as an amide donor for providing the
post-translational amide modification in each case.
Both putative mature peptides were subjected to bioinformatics analysis by use of the National
Center for Biotechnology Information (NCBI ) protein Basic Local Alignment Search Tool (BLASTp)
program, which found that PS-Du and PS-Co were new phylloseptins. PS-Du and PS-Co showed
a high degree of structural identity to phylloseptins from other Phyllomedusa frogs, including the
well-studied PSN-9 (accession No. Q0VZ38) from Phyllomedusa hypochondrialis and PSN-1 (accession
No. Q800R3) from Phyllomedusa bicolor. The alignment of open-reading frame nucleotide and amino
acid sequences of PS-DU, PS-Co, PSN-9 and PSN-1, was established by use of Vector NTI software
(Version 11.5, 2010, Life Technologies, Carlsbad, CA, USA), and these are shown in Figures 2 and 3.
The nucleotide sequence of both PS-Du and PS-Co precursors, have been deposited in the European
Molecular Biology Laboratory (EMBL) Nucleotide Sequence Database under the accession codes
LN999522 and LN999523.
The alignments demonstrated a high degree of similarity in both nucleotide and deduced amino
acid sequences. More than 85% nucleic acid sequence identities between these four full-length
nucleotide sequences were observed, excluding the gaps. This demonstrated highly-conserved
genetic information from this subfamily. Meanwhile, the deduced amino acid sequences of these four
precursors demonstrated the same topological structures and these are shown in Figure 3.
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Figure 1. Nucleotide and translated open-reading frame amino acid sequences of cloned cDNAs 
encoding precursors of novel phylloseptin peptides, PS-Du (A) and PS-Co (B). Putative signal 
peptides are double-underlined, mature peptides are single–underlined and stop codons are 
indicated by asterisks. 
(A) 
 
  M  A  F  L   K  K  S   L  F  L   V  L  F  F   G  L  V 
       1ATGGCTTTCT TGAAGAAATC TCTTTTCCTT GTACTATTCT TTGGATTGGT 
 TACCGAAAGA ACTTCTTTAG AGAAAAGGAA CATGATAAGA AACCTAACCA 
  S  L  S   I  C  E  E   E  K  R   E  T  E   E  E  E  N 
      51TTCCCTTTCC ATCTGTGAAG AAGAGAAAAG AGAGACAGAA GAAGAAGAAA 
 AAGGGAAAGG TAGACACTTC TTCTCTTTTC TCTCTGTCTT CTTCTTCTTT 
    N  Q  E   E  D  D   K  S  E  E   K  R  F   F  S  M 
     101ATAATCAAGA GGAAGATGAC AAAAGTGAAG AGAAGAGATT CTTCAGCATG 
 TATTAGTTCT CCTTCTACTG TTTTCACTTC TCTTCTCTAA GAAGTCGTAC 
  I  P  K  I   A  T  G   I  A  S   L  V  K  N   L  G  * 
     151ATACCAAAGA TAGCAACTGG AATAGCTTCA CTTGTTAAAA ACTTAGGTTA 
 TATGGTTTCT ATCGTTGACC TTATCGAAGT GAACAATTTT TGAATCCAAT 
   
     201ATACAATGTA ACATTTCATA ACTCTAAAGA GCACAATTAT CAATAATTGT 
 TATGTTACAT TGTAAAGTAT TGAGATTTCT CGTGTTAATA GTTATTAACA 
     251TCTCATAATA CATTAAAGCA TATTTAACCA AAAAAAAAAA AAAAAAAAAA 
 AGAGTATTAT GTAATTTCGT ATAAATTGGT TTTTTTTTTT TTTTTTTTTT 
 
 
(B) 
  M  A  F  L   K  K  S   L  F  L   V  L  F  F   G  L  V 
       1ATGGCTTTCT TGAAGAAATC TCTTTTCCTT GTACTATTCT TTGGATTGGT 
 TACCGAAAGA ACTTCTTTAG AGAAAAGGAA CATGATAAGA AACCTAACCA 
  S  F  S   I  C  E  E   E  K  R   E  T  E   E  K  E  N 
      51TTCTTTTTCC ATCTGTGAAG AAGAGAAAAG AGAGACTGAA GAGAAAGAAA 
 AAGAAAAAGG TAGACACTTC TTCTCTTTTC TCTCTGACTT CTCTTTCTTT 
    D  Q  E   E  D  D   K  S  E  E   K  R  F   L  S  M 
     101ATGATCAAGA GGAAGATGAT AAAAGTGAAG AGAAGAGATT CCTCAGCATG 
 TACTAGTTCT CCTTCTACTA TTTTCACTTC TCTTCTCTAA GGAGTCGTAC 
  I  P  K  I   A  G  G   I  A  S   L  V  K  N   L  G  * 
     151ATACCAAAGA TAGCAGGTGG AATAGCTTCA CTTGTTAAAA ACTTAGGTTA 
 TATGGTTTCT ATCGTCCACC TTATCGAAGT GAACAATTTT TGAATCCAAT 
  
     201ATACAATGTA ACATTTCATA ACTCTAAGGA GCACAATTAT CAATAATTGT 
 TATGTTACAT TGTAAAGTAT TGAGATTCCT CGTGTTAATA GTTATTAACA 
     251TCTCAAAATA CATTAAAGCA TATTTAACCA ACAAAAAAAA AAAAAAAAAA 
 AGAGTTTTAT GTAATTTCGT ATAAATTGGT TGTTTTTTTT TTTTTTTTTT 
     301AAAAAAAA 
 TTTTTTTT 
i r . cl ti tr sl t -r i fr i ci s c s f cl c s
e c i rec rs rs f el ll se ti e ti es, S- ( ) a S- ( ). tati e si al
pepti es are double-underlined, mature peptides are single–underlined and stop codons are indicated
by asterisks.
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precursors, PSN-9 (Accession No.Q0VZ38), PSN-1 (Accession No.Q800R3), PS-Du and PS-Co, 
demonstrating 7-regions of topological structures with asterisks indicating sites of amino acid 
sequence identities. 1—Putative signal peptide; 2 & 4—Acidic amino acid residue-rich spacer 
peptides; 3 & 5—Dibasic propeptide convertase processing site; 6—Mature PS peptide; 7—Glycine 
residue amide donor. 
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PS-Co   (1) ----------------------------------------------ATGG 
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PS-Co  (5) CTTTCTTGAAGAAATCTCTTTTCCTTGTACTATTCTTTGGATTGGTTTCC 
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PBN-1     (101) CTTTCCATCTGTGAAGAAGAGAAAAGAGAGACTGAAGAGAAAGAATATGA 
PS-Du      (55) TTTTCCATCTGTGAAGAAGAGAAAAGAGAGACTGAAGAGAAAGAAAATGA 
PS-Co      (55) CTTTCCATCTGTGAAGAAGAGAAAAGAGAGACAGAAGAAGAAGAAAATAA 
 
           151                                            200 
PSN-9     (139) TCAAGAGGAAGATGATAAAAGTGAAGAGAAGAGATTCTTAGGCTTGCTAC 
PBN-1     (151) TCAAGGGGAAGATGATAAAAGTGAAGAGAAGAGATTCCTCAGCTTGATAC 
PS-Du     (105) TCAAGAGGAAGATGATAAAAGTGAAGAGAAGAGATTCCTCAGCATGATAC 
PS-Co     (105) TCAAGAGGAAGATGACAAAAGTGAAGAGAAGAGATTCTTCAGCATGATAC 
                                      
      201                                            250 
PSN-9     (189) CAAGTATAGTGTCTGGAGCAGTTTCACTTGTTAAAAAATTAGGTTAATAC 
PBN-1     (201) CACATATAGTATCTGGAGTAGCTGCACTTGCTAAACATTTAGGTTAATAA 
PS-Du     (155) CAAAGATAGCAGGTGGAATAGCTTCACTTGTTAAAAACTTAGGTTAATAC 
PS-Co     (155) CAAAGATAGCAACTGGAATAGCTTCACTTGTTAAAAACTTAGGTTAATAC 
 
      251                                            300 
PSN-9     (239) AATTTAATA-----A--CT------------------------------- 
PBN-1     (251) AATGTATAA-----T--GT--AATTA-----------AATAATTGTCCCC 
PS-Du     (205) AATGTAACATTTCATAACTCTAAGGAGCACAATTATCAATAATTGTTCTC 
PS-Co     (205) AATGTAACATTTCATAACTCTAAAGAGCACAATTATCAATAATTGTTCTC 
                                      
      301                                            350 
PSN-9     (251) -------------------------------------------------- 
PBN-1     (281) AAAATACATTAAAGCATATTTAACCAGCAAAAAAAA-------------- 
PS-Du     (255) AAAATACATTAAAGCATATTTAACCAACAAAAAAAAAAAAAAAAAAAAAA 
PS-Co     (255) ATAATACATTAAAGCATATTTAACCAAAAAAAAAAAAAAAAAAAAA---- 
                                                         1            2    3                   4                                5        6                     7 
 
PSN-9   MAFLKKSLFLVLFLGLVSLSIC  EEE   KR   ETEEEENDQEEDDKSEE  KR   FLGLLPSIVSGAVSLVKKL   G 
 
PBN-1   MAFLKKSLFLVLFLGLVSLSIC  EEE   KR   ETEEKEYDQGEDDKSEE  KR   FLSLIPHIVSGVAALAKHL   G 
  
PS-Du   MAFLKKSLFLVLFFGLVSLSIC  EEE   KR   ETEEEENNQEEDDKSEE  KR   FFSMIPKIATGIASLVKNL   G 
  
PS-Co   MAFLKKSLFLVLFFGLVSFSIC  EEE   KR   ETEEKENDQEEDDKSEE  KR   FLSMIPKIAGGIASLVKNL   G 
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Figure 2. Alignments of the full-length nucleotide sequences of cDNAs encoding four PS
precursors, PSN-9 (Accession No. Q0VZ38), PSN-1 (Accession No. Q800R3), PS-Du and PS-Co.
Black shading indicates identical sequences between four individual precursors and gaps are inserted
to maximize alignments.
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2.2. Fractionation of Skin Secretions, Identification and Structural Characterisation of PS-Du and PS-Co
The lyophilized crude skin secretions of Phyllomedusa duellmani and Phyllomedusa coelestis were
respectively fractioned by reversed-phase high-performance liquid chromatography (RP-HPLC) and
the chromatograms are shown in Figures 4A and 5A, with arrows indicating the retention times/elution
positions of peptides with masses coincident with the approximate predicted molecular masses of
PS-Du and PS-Co. The HPLC elution profile of synthetic PS-Du and its co-elution profile with the crude
skin secretion of Phyllomedusa duellmani is shown in Figure 4B,C. Likewise, the HPLC elution profile
of synthetic PS-Co and its co-elution profile with the crude skin secretion of Phyllomedusa coelestis is
shown in Figure 5B,C. The masses of the peptides in fractions corresponding to PS-Du and PS-Co
were detected using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF MS) on a linear time-of-flight Voyager DE mass spectrometer (Perceptive Biosystem,
Bedford, MA, USA) (Figure 6). The amino acid sequence of PS-Du and PS-Co were further analysed by
MS/MS fragmentation sequencing shown in Figure 7A, B. The amino acid sequences of the mature
peptides, PS-Du and PS-Co, were thus unequivocally identified and the glycine (G) residue at the
carboxyl terminus of both precursors was also confirmed as an amide donor.
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relevant position to that in (A); Co-elution reverse phase HPLC chromatogram of synthetic PS-Du 
added to crude skin secretion of Phyllomedusa duellmani (C) with absorbance peak at relevant position 
to that in (A). The Y-axis shows the relative absorbance in absorbance units at 214 nm and the X-axis 
shows the retention time in minutes. 
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Figure 4. Reverse-phase high-performance liquid chromatography (RP-HPLC) chromatogram of the
skin secretion of Phyllomedusa duellmani (A) with arrow showing the absorbance peak corresponding to
natural PS-Du. Reverse phase HPLC profile of synthetic PS-Du (B) with absorbance peak at relevant
position to that in (A); Co-elution reverse phase HPLC chromatogram of synthetic PS-Du added to
crude skin secretion of Phyllomedusa duellmani (C) with absorbance peak at relevant position to that in
(A). The Y-axis shows the relative absorbance in absorbance units at 214 nm and the X-axis shows the
retention time in minutes.
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arrow showing the absorbance peak corresponding to natural PS-Co. Reverse phase HPLC profile of
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Figure 7. Electrospray ion-trap MS/MSfragmentation datasets and MS/MS fragment scans derived 
from ions corresponding in molecular mass to PS-Du (A) and PS-Co (B). Expected singly- and 
doubly-charged b-ions and y-ions arising from MS/MS fragmentation were predicted using the MS 
Product programme available through Protein Prospector on-line. Actual fragment ions observed 
following MS/MS fragmentation are indicated in blue and red typefaces.2.3. Secondary Structure 
Prediction of PS-Du and PS-Co. 
The secondary structures of PS-Du and PS-Co were predicted through software modeling on 
the SWISS-Model (http://swissmodel.expasy.org) [21–24]. The server analysed PS-Du (Figure 8A) 
and PS-Co (Figure 8B) and found that both peptides contained a large proportion of α-helical 
domain. 
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Figure 7. Electrospray ion-trap MS/MSfragmentation datasets and MS/MS fragment scans derived
from ions corresponding in molecular mass to PS-Du (A) and PS-Co (B). Expected singly- and
doubly-charged b-ions and y-ions arising from MS/MS fragmentation were predicted using the MS
Product programme available through Protein Prospector on-line. Actual fragment ions observed
following MS/MS fragmentation are indicated in blue and red typefaces.
2.3. Secondary Structure Prediction of PS-Du and PS-Co.
The secondary structures of PS-Du and PS-Co were predicted through software modeling on the
SWISS-Model (http://swissmodel.expasy.org) [21–24]. The server analysed PS-Du (Figure 8A) and
PS-Co (Figure 8B) and found that both peptides contained a large proportion of α-helical domain.
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Figure 8. Secondary structure prediction analysis of PS-Du (A) and PS-Co (B) using SWISS-Model 
(http://swissmodel.expasy.org) suggesting a large proportion of α-helix in both. The red and green 
lines indicate the probability of forming regions of helix and coil, respectively. 
2.4. Antimicrobial and Haemolytic Activities of PS-Du and PS-Co and Those of Their Structurally-Modified 
Analogues, PS-Du K7H, and PS-Co K7H 
Synthetic PS-Du and PS-Co and their respective structurally-modified analogues, PS-Du K7H 
and PS-Co K7H, exhibited growth inhibitory activity against the Gram-positive bacterium, S. aureus, 
the Gram-negative bacterium, E. coli and the potentially-pathogenic yeast, C. albicans. MICs 
(minimal inhibitory concentrations）of all four peptides are summarised in Table 1 and MIC curves 
are shown in Figure 9. The skin secretion-derived peptides, PS-Du and PS-Co, showed similar 
potencies with MIC values of 8 mg/L against S. aureus, 128 mg/L against E. coli and 16 mg/L against C. 
albicans. The modified peptide analogues, PS-Du K7H and PS-Co K7H, showed similar inhibition 
with MIC values of 32 mg/L towards S. aureus, 512 mg/L towards E. coli and 64 mg/L towards C. 
albicans. Both natural peptides, PS-Du and PS-Co, and modified peptides, PS-Du K7H and PS-Co 
K7H, exhibited moderate haemolytic effects on horse red blood cells as shown in Figure 10. 
Table 1. The minimal inhibitory concentrations (MICs) of PS-Du, PS-Co, PS-Du K7H and PS-Co K7H, 
against the three different microorganisms. 
Peptide Name Molecular Mass(Da) 
MIC 
S. aureus E. coli C. albicans 
PS-Du 2049.5 
8 mg/L 128 mg/L 16 mg/L 
(3.90 µM) (62.45 µM) (7.81 µM) 
PS-Co 1971.5 
8 mg/L 128 mg/L 16 mg/L 
(4.06 µM) (64.93 µM) (8.12 µM) 
PS-Du K7H 2057.1 
32 mg/L 512 mg/L 64 mg/L 
(15.56 µM) (248.89 µM) (31.12 µM) 
PS-Co K7H 1979.1 
32 mg/L 512 mg/L 64 mg/L 
(16.17 µM) (258.70 µM) (32.34 µM) 
Figure 8. Secondary structure prediction analysis of PS-Du (A) and PS-Co (B) using SWISS-Model
(http://swissmodel.expasy.org) suggesting a large proportion of α-helix in both. The red and green
lines indicate the probability of forming regions of helix and coil, respectively.
2.4. Antimicrobial and Haemolytic Activities of PS-Du and PS-Co and Those of Their Structurally-Modified
Analogues, PS-Du K7H, and PS-Co K7H
Synthetic PS-Du and PS-Co and their respective structurally-modified analogues, PS-Du K7H
and PS-Co K7H, exhibited growth inhibitory activity against the Gram-positive bacterium, S. aureus,
the Gram-negative bacterium, E. coli and the potentially-pathogenic yeast, C. albicans. MICs (minimal
inhibitory concentrations) of all four peptides are summarised in Table 1 and MIC curves are shown
in Figure 9. The skin secretion-derived peptides, PS-Du and PS-Co, showed similar potencies with
MIC values of 8 mg/L against S. aureus, 128 mg/L against E. coli and 16 mg/L against C. albicans.
The modified peptide analogues, PS-Du K7H and PS-Co K7H, showed similar inhibition with MIC
values of 32 mg/L towards S. aureus, 512 mg/L towards E. coli and 64 mg/L towards C. albicans.
Both natural peptides, PS-Du and PS-Co, and modified peptides, PS-Du K7H and PS-Co K7H, exhibited
moderate haemolytic effects on horse red blood cells as shown in Figure 10.
Table 1. The minimal inhibitory concentrations (MICs) of PS-Du, PS-Co, PS-Du K7H and PS-Co K7H,
against the three different microorganisms.
Peptide Name Molecular Mass(Da)
MIC
S. aureus E. coli C. albicans
PS-Du 2049.5
8 mg/L 128 mg/L 16 mg/L
(3.90 µM) (62.45 µM) (7.81 µM)
PS-Co 1971.5
8 mg/L 128 mg/L 16 mg/L
(4.06 µM) (64.93 µM) (8.12 µM)
PS-Du K7H 2057.1
32 mg/L 512 mg/L 64 mg/L
(15.56 µM) (248.89 µM) (31.12 µM)
PS-Co K7H 1979.1
32 mg/L 512 mg/L 64 mg/L
(16.17 µM) (258.70 µM) (32.34 µM)
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Figure 9. Minimal inhibitory concentration (MIC) curves obtained following incubation of C. albicans, 
E. coli, and S. aureus with the natural peptides, PS-Du (A), PS-Co (B) and the structurally-modified 
peptides, PS-Du K7H (C) and PS-Co K7H (D) at concentrations ranging from 512 mg/L to 1 mg/L. 
The blank control was established by culture medium and the positive control was represented by 
growth culture. Data represent means ± SEM (standard error of the mean) of 5 replicates. 
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Figure 10. The haemolytic activity of PS-Du, PD-Co (A) and PS-Du K7H PS-Co K7H (B) at 
concentrations ranging from 512 mg/L to 1 mg/L. Percentage of haemolysis was evaluated and 
calculated by comparing values those of the positive control established by using 1% Triton X-100. 
Data represent means ± SEM of 5 replicates. 
2.5. Anti-Biofilm and Cell-Membrane Permeabilization Activities of Natural Peptides, PS-Du and PS-Co 
The activities of PS-Du and PS-Co against S. aureus biofilm were tested and both peptides 
possessed biofilm eradication capability with an MBEC (minimal biofilm eradication concentration) 
of 16 mg/L (Figure 11). Additionally, PS-Du and PS-Co had the capability of cell-membrane 
permeabilization at concentrations of 8 mg/L and 16 mg/L, respectively (Figure 12). Each assay was 
carried out over at least three individual experiments with three replicates in each. 
Figure 9. Minimal inhibitory concentration (MIC) curves obtained following incubation of C. albicans,
E. coli, and S. aureus with the natural peptides, PS-Du (A), PS-Co (B) and the structurally-modified
peptides, PS-Du K7H (C) and PS-Co K7H (D) at concentrations ranging from 512 mg/L to 1 mg/L.
The blank control was established by culture medium and the positive control was represented by
growth culture. Data represent means ± SE (standard error of the ean) of 5 replicates.
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Figure 10. The haemolytic activity of PS-Du, PD-Co (A) and PS-Du K7H PS-Co K7H (B) at
concentrations ranging from 512 mg/L to 1 mg/L. Percentage of haemolysis was evaluated and
calculated by comparing values those of the positive control established by using 1% Triton X-100.
Data represent means ± SEM of 5 replicates.
2.5. Anti-Biofilm and Cell-Membrane Permeabilization Activities of Natural Peptides, PS-Du and PS-Co
The activities of PS-Du and PS-Co against S. aureus biofilm were tested and both peptides
possessed biofilm eradication capability with an MBEC (minimal biofilm eradication concentration)
of 16 mg/L (Figure 11). Additionally, PS-Du and PS-Co had the capability of cell-membrane
Toxins 2016, 8, 255 13 of 21
permeabilization at concentrations of 8 mg/L and 16 mg/L, respectively (Figure 12). Each assay
was carried out over at least three individual experiments with three replicates in each.
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against S. aureus biofilm with peptide concentrations ranging from 4 mg/L (0.5 MIC) to 64 mg/L (8 
MIC). Blank control was set up with culture medium, and positive control was represented by S. 
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Figure 12. Cell-membrane permeability effects of PS-Du (A) and PS-Co (B) on S. aureus detected by 
the SYTOX Green (Life technologies, Carlsbad, CA, USA) assay at peptide concentrations 
corresponding to 1 MIC, 2 MIC and 4 MIC. Positive membrane permeabilization was obtained 
following incubation of S. aureus with 70% isopropyl alcohol. The negative control was represented 
as vehicle only. Data represent means ± SEM of 5 replicates. 
3. Experimental Section 
3.1. “Shotgun” Cloning of Novel Phylloseptin Precursor-Encoding cDNAs from Skin Secretion-Derived 
cDNA Libraries of Phyllomedusa Duellmani and Phyllomedusa Coelestis 
Lyophilised skin secretions of Phyllomedusa duellmani and Phyllomedusa coelestis were obtained 
from Mr. Juan Chavez, Venom Peru Company (PeruBiotech E.I.R.L, Huánuco, Peru). 
The lyophilised skin secretions from both species were separately dissolved in 1 mL of cell 
lysis/binding buffer (Life technologies, Oslo, Norway). Magnetic oligo-dT beads were used to isolate 
the polyadenylated mRNA following the procedure described by the manufacturer (Life 
technologies, Oslo, Norway). To acquire full-length prepropeptide nucleic acid sequence data, a 
SMART-RACE kit (Clontech, Palo Alto, CA, USA) was employed with a nested universal primer 
(NUP) (supplied in the kit) and a degenerate primer pool (5′- 
ACTTTCYGAWTTRYAAGMCCAAABATG-3′ Y = C + T, W = A + T, R = A + G, M = A + C, B = T + C + 
Figure 11. The MBEC (minimal biofilm eradication concentration) of PS-Du (A) and PS-Co (B) against
S. aureus biofilm with peptide concentrations ranging from 4 mg/L (0.5 MIC) to 64 mg/L (8 MIC).
Blank control was set up with culture medium, and positive control was represented by S. aureus
biofilm growth culture. Data represent means ± SEM of 9 replicates.
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Figure 12. Cell-membrane permeability effects of PS-Du (A) and PS-Co (B) on S. aureus detected by the
SYTOX Green (Life technologies, Carlsbad, CA, USA) assay at peptide concentrations corresponding
to 1 MIC, 2 MIC and 4 MIC. Positive membrane permeabilization was obtained following incubation
of S. aureus with 70% isopropyl alcohol. The negative control was represented as vehicle only.
Data represent means ± SEM of 5 replicates.
3. Experimental Section
3.1. “Shotgun” Cloning of Novel Phylloseptin Precursor-Encoding cDNAs from Skin Secretion-Derived cDNA
Libraries of Phyllomedusa Du llmani and Phyllomedusa Coelestis
Lyophilised skin secretions of Phyllomedusa duellmani and Phyllomedusa coelesti wer obtained
from Mr. Juan Chavez, Venom Peru Company (PeruBiotech E.I.R.L, Huánuco, Peru).
The lyophilised skin secretions from both species wer separ tely dissolved in 1 mL of cell
lysis/binding buffer (Life technol gies, Oslo, Norway). Magnetic oligo-dT beads wer used to isolate
the polyadenylated mRNA following the procedure describ d by the manufacturer (Life technologies,
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Oslo, Norway). To acquire full-length prepropeptide nucleic acid sequence data, a SMART-RACE kit
(Clontech, Palo Alto, CA, USA) was employed with a nested universal primer (NUP) (supplied in
the kit) and a degenerate primer pool (5′- ACTTTCYGAWTTRYAAGMCCAAABATG-3′ Y = C + T,
W = A + T, R = A + G, M = A + C, B = T + C + G) designed to a segment of the 5′-untranslated region
of phylloxin cDNA from Phyllomedusa bicolor (EMBL Accession No. AJ251876) and the opioid peptide
cDNA from Pachymedusa dacnicolor EMBL Accession No. AJ005443). The procedure was again as
outlined by the manufacturer. The PCR cycling program was as follows: Initial denaturation step:
90 s at 9 4 ◦C; 35 cycles: denaturation 30 s at 94 ◦C, primer annealing for 30 s at 58 ◦C; extension for
180 s at 72 ◦C. PCR products were analysed by DNA-gel electrophoresis, purified and cloned using
a pGEM®-T Easy vector system (Promega Corporation, Southampton, UK) and the selected samples
were sequenced using an ABI 3100 automated sequencer (Applied Biosystems, Foster City, CA, USA).
The Blast Alignment Search Tool (BLAST) of the National Center for Biotechnology Information (NCBI)
was used to study the similarities of the novel amino acid sequences with the known sequences
in the BLASTp database. Alignments were established to compare the novel sequences with the
two identified sequences, PSN-9 (Accession No. Q0VZ38) and PBN-1 (Accession No. Q800R3).
3.2. Chromatographic Isolation and Structural Characterisation of the Two Novel Phylloseptins from the Skin
Secretions of Phyllomedusa Duellmani and Phyllomedusa Coelestis
Seven mg of lyophilised skin secretions from each species were separately dissolved using 1.25 mL
of trifluoroacetic acid (TFA)/water (0.05:99.95, v/v). The insoluble microparticulates were cleared
by centrifugation (2500× g for 5 min). The clear supernatants were carefully decanted into a 2 mL
screw top vial (Waters, Milford, MA, USA) and placed on an autosampler. The RP-HPLC system used
consisted of a Waters 2707 auto sampler, a Waters 1525 HPLC pump and a Waters 2489 UV detector
(Waters, USA). The sample solution was separated using a Jupiter C5 reverse phase HPLC column
(250 mm × 4.6 mm, Phenomenex, Macclesfield, UK). A linear gradient formed from 0.05/99.95 (v/v)
TFA/water to 0.05/19.95/80.0 (v/v/v) TFA/water/acetonitrile in 240 min at a flow rate of 1 mL/min
was employed to elute peptides. Fractions were collected at minute intervals by an automated fraction
collector (GE Healthcare, Little Chalfont, UK). Each fraction was subjected to molecular mass analysis
by means of a Voyager DE MALDI linear time-of-flight mass spectrometer (Perseptive Biosystems,
Bedford, MA, USA) to construct a mass spectral library of skin secretion peptides. The instrument was
calibrated in the range of 1–4 kDa and the accuracy of mass determinations was ±0.1%. The computed
molecular masses of predicted mature peptides deduced from encoded cDNA were used to interrogate
the mass spectral library to identify the putative peptides. The fractions containing the peptides of
identical masses to putative novel cDNA-encoded peptides were each subjected to primary structural
analysis by MS/MS fragmentation sequencing using an LCQ-Fleet ion-trap mass spectrometer (Thermo
Fisher Scientific, San Francisco, CA, USA).
In addition to the primary structure characterisation of the two novel peptides, further-secondary
structure prediction was performed using the bioinformatics tool, SWISS-MODEL [21–24].
3.3. Solid-Phase Peptide Synthesis of the Two Novel Peptides and Their Structurally-Modified Analogues
Four peptides were chemically-synthesised by solid phase Fmoc chemistry using a Tribute
automated solid-phase peptide synthesiser 4 (Protein Technologies, Tucson, AZ, USA). The amino acid
sequences of the two novel frog skin phylloseptin peptides were FFSMIPKIATGIASLVKNL-NH2 and
FLSMIPKIAGGIASLVKNL-NH2, and they were named PS-Du and PS-Co, respectively. The amino
acid sequences of the two single-site modified analogues were FFSMIPHIATGIASLVKNL-NH2
and FLSMIPHIAGGIASLVKNL-NH2. Both contained a His for Lys substitution at position 7,
and they were named as PS-Du K7H and PS-Co K7H. All the dry amino acids were weighed
and mixed with 2-(1H-benzotriazol-1-yl)-1,1,3,3,-tetramethyluronium hexafluorophosphate (HBTU)
activtator and transferred to the reaction vessel containing rink amide MBHA resin on the synthesiser.
The deprotection of the Fmoc groups was performed in 20% piperidine in dimethylformamide (DMF).
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The peptide bond coupling was activated and completed in 1M 11% N-Methylmorpholine (NMM)
in DMF. Synthesised peptides and side chain protecting groups were cleaved from the resin using
95% trifluoroacetic acid (TFA), 2.5% triisopropylsilane (TIPS) and 2.5% water. The confirmation of the
primary structure of the synthetic peptides and their purity was accomplished by reverse-phase HPLC
and using MALDI-TOF and an LCQ-Fleet electrospray ion-trap mass spectrometer (Thermo Fisher
Scientific, San Francisco, CA, USA).
3.4. RP-HPLC Analysis of the Two Novel Synthetic Peptides and Co-Elution Profiling of These Two Peptides
with Their Respective Skin Secretion Counterparts
PS-Du and PS-Co were dissolved using 0.5% TFA/water solution to a concentration of 1 mg/L.
They were respectively analysed by injecting 1200 µL synthetic peptide solution into the Waters
RP-HPLC system using the same gradient as described in Section 3.2.
An additional 7 mg of each lyophilized skin secretion from Phyllomedusa duellmani and
Phyllomedusa coelestis, were dissolved separately as described in Section 3.2. Afterwards, 200 µL
of synthetic PS-Du and PS-Co solutions mentioned above were mixed with corresponding dissolved
skin secretions. Both mixtures of 200 µL of peptide solution and 1000 µL of skin secretion solution
were analysed using the Waters RP-HPLC system with the same gradient as described in Section 3.2.
3.5. Antimicrobial Activity Assays with the Two Novel Peptides and Their Structurally-Modified Analogues
Antimicrobial activity of each peptide was assessed by determination of minimal inhibitory
concentrations (MICs), defined as the minimal concentration of antibiotic which inhibits growth
following an overnight incubation with microorganisms. Escherichia coli (NCTC 10418) as a standard
Gram-negative bacterium, Staphylococcus aureus (NCTC 10788) as a standard Gram-positive bacterium
and Candida albicans (NCPF 1467) as a standard pathogenic yeast, were used in these experiments
and were grown in Mueller-Hinton broth (MHB) for 18 h. Peptides were initially made as stock
solutions using 1% dimethyl sulfoxide (DMSO) in phosphate-buffered saline (PBS), and the working
solutions were prepared from these to achieve final concentrations of peptides from 512 to 1 mg/L.
Peptide solutions were incubated with growth cultures (106 colony forming units (CFU)/mL) in
96-well plates for 18 h at 37 ◦C. The growth of bacteria/yeast was detected by optical density (OD)
measurements at a wavelength of 550 nm. The minimal inhibitory concentrations (MICs) of all four
synthetic peptides were determined as the lowest concentration of peptide where no growth was
detectable using an ELISA plate reader (Biolise BioTek EL808, Winooski, VT, USA).
3.6. Haemolysis Assay of the Two Novel Peptides and Their Modified Analogues
The haemolysis assay was performed using erythrocytes prepared from defibrinated horse blood
(TCS Biosciences Ltd., Buckingham, UK). Two hundred µL of a 4% (v/v) suspension of erythrocytes in
phosphate-buffered saline (PBS) were incubated with different concentrations of peptides prepared
in PBS from 512 to 1 mg/L at 37 ◦C for 2 h. Lysis of erythrocytes was assessed by measurement of
optical density at 550 nm using an ELISA plate reader (Biolise BioTek EL808, Winooski, VT, USA).
Negative controls employed consisted of a 4% (v/v) erythrocyte suspension and PBS in equal volumes.
Positive controls consisted of a 4% (v/v) erythrocyte suspension and an equal volume of 2% (v/v) of
the non-ionic detergent, Triton X-100 (Sigma–Aldrich, St. Louis, MO, USA), in PBS solution.
3.7. Anti-Biofilm Activities of the Two Novel Peptides Tested on S. aureus Biofilm
The anti-biofilm activities of the two novel peptides were tested on S. aureus biofilm following
a standard method as per the manufacturer’s instructions (Innovotech, Edmonton, AB, Canada)
for evaluating the MBEC (minimal biofilm eradication concentration). S. aureus (NCTC 10788) was
incubated in MHB overnight at 37 ◦C and subcultured before being seeded onto the plate. 150 µL of
105 CFU/mL bacteria culture were inoculated into each well of the MBEC assay plate (Innovotech).
The biofilm was formed on the purpose-designed pegs after incubation for 48 h in an orbital-incubator
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at 37 ◦C, 150 rpm and appropriate humidity. Subsequently, a challenge plate was filled with 200 µL of
peptide working solutions of each concentration in TSB and the lid with pegs was inserted into this
plate after PBS washing steps. After incubation for 24 h at 37 ◦C, the pegs were washed using PBS
again and then transferred into a recovery plate with 200 µL recovery solution (MHB/neutralising
agents 20/0.5 (v/v)) in each well. A 30-min ultrasonic treatment was employed to disrupt the biofilm
from the pegs and the recovery plate was incubated for another 24 h at 37 ◦C. The 96-well plate was
analysed using an ELISA plate reader (Biolise BioTek EL808, Winooski, VT, USA) as described in the
previous section. The minimal biofilm eradication concentration (MBEC) is defined as the lowest
concentration where no growth of bacteria was detectable after biofilm was ultrasonically disrupted
and further incubated in the recovery plate.
3.8. Bacterial Cell Membrane Permeability Assay of the Two Novel Peptides Using S. aureus
The membrane permeability assay was carried out using SYTOX Green Nucleic Acid Stain
(Life technologies, Carlsbad, CA, USA) as descried by Roth et al [25]. Bacteria were incubated in
Tryptic Soy Broth (TSB) (Sigma–Aldrich, St. Louis, MO, USA) at 37 ◦C overnight, after which 200 µL
of bacterial culture was inoculated into 25 mL TSB and incubated at 37 ◦C for 3 h to achieve the
logarithmic growth phase. Then, bacterial cells were harvested by centrifugation at 1000× g for 10 min
at 4 ◦C, followed by two cell washing processes with 5% TSB in 0.85% NaCl solution. The washed
bacterial cells were suspended in 5%TSB to achieve 1 × 108 CFU/mL which was detectable at OD
590 nm = 0.7. Each well of the sample groups in a black 96 well plate (Fisher Scientific, Leicestershire,
UK) contained a volume of 50 µL of bacterial suspension and 50 µL of peptide solution. Each well of
the negative control group was constituted by a volume of 50 µL of bacterial suspension and 40 µL of
5% TSB. The positive control group was established by using 70% isopropanol-permeabilised bacterial
cells, as described by Roth et al. [25], and was made by a volume of 50 µL of permeabilised bacterial cell
suspension and 40 µL of 5% TSB. 10 µL of SYTOX green nucleic acid stain was added to each well to
a final concentration of 5 µM. Meanwhile, the background fluorescence was measured using a volume
of 90 µL 5% TSB and 10 µL SYTOX green nucleic acid stain at the same concentration. The black
plate was incubated for 2 h at 37 ◦C in the dark. The fluorescent intensity of each well was recorded
using an ELISA plate reader (Biolise BioTek EL808, Winooski, VT, USA) with excitation at 485 nm and
emission at 528 nm.
3.9. Statistical Analysis
Data were subjected to statistical analysis using Prism (Version 5.0; GraphPad Software Inc.,
San Diego, CA, USA). Error bars in the graphs represent standard error of the mean (SEM) with
experiments performed on more than three sets of replicates.
4. Discussion
Amphibian skin secretions have been proven to be a rich source of biomolecules for current
lead drug discovery [26,27]. Frog skin peptides, as the predominant compounds in the secretions,
exhibit a great potential for the treatment of many diseases in the areas of cancer and infection [8,
28,29]. Phyllomedusine leaf frogs are one of the most remarkable subfamilies of amphibians and
they have contributed much to the study of skin peptides in that they contain many varieties of
unique bioactive peptides, such as phylloseptins, dermaseptins, medusins and phyllokinins [13,30,31].
Therefore, it is essential to continue investigations on the species of this subfamily to identify more
novel peptides. So far, only 16 species have been studied from 59 species of this subfamily [12,32].
In this study, two virtually unstudied species of phyllomedusine frogs, Phyllomedusa duellmani and
Phyllomedusa coelestis, were chosen. Unlike the well-studied species which are widely-distributed
in South America, these two species are limited to remote areas of northern Peru with colonies
only recorded in specific localities in mountainous areas. Phyllomedusa duellmani as an example, has
an altitudinal range of 1850–1910 m above sea level [20]. These strict living environments may influence
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gene expression and contribute to unique skin defence peptide generation, some of which may show
a great potential in drug lead discovery.
In this study, two novel phylloseptin peptides, named PS-Du and PS-Co, from the skin secretions
of Phyllomedusa duellmani and Phyllomedusa coelestis, respectively, were discovered. Since Leite
reported the prototype phylloseptin in 2005, more than 40 novel phylloseptin (PS) peptides with
highly-conserved amino acid sequences from the skin secretions of phyllomedusine leaf frogs,
have been discovered [14–18,33]. According to the records in the Uniprot database (The Uniprot
Consortium), PS peptides show some common characteristics with the presence of an N-terminal Phe
residue, a Pro residue at position 6, a His residue at position 7 and a variable amidated C-terminal
residue. Most of their primary structural characteristics are highly-conserved such as the N-terminal
hexapeptide, FLSLIP- (Figure 13). Some phylloseptins possess different amino acids within this
hexapeptide region with Leu and Ser residues replaced by Ile and Gly, respectively. This is a common
phenomenon occurring in discrete peptide families among amphibian species. The different isoforms
within peptide families provide useful phylogenetic information on the genetic mutations which
have occurred during speciation, offering great benefits for the species to increase the survival
capabilifrom cruel natural selection. Here, the encoded cDNAs isolated from Phyllomedusa duellmani
and Phyllomedusa coelestis, proved to be highly-conserved.
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Interestingly, such topological structural conservation is a very common phenomenon in other
amphibian skin defence peptide families including dermaseptins, medusins and phyllokinins, from
skin secretion of phyllomedusine leaf frogs [15,16,31]. These features have further revealed that
they have developed a unique defence peptide expression approach from the precursors to the
mature peptides.
PS-Co and PS-Du were extremely similar in structure with only two differences in amino acid
sequence in position 2 and position 10. In addition, their secondary structures as predicted by
SWISS-MODEL modeling software, showed a large proportion of α-helix from position 4 to position 18.
Interestingly, unlike one of the common features of most phylloseptin peptides, PS-Co and
PS-Du both demonstrated a lysine (K) substitution for histidine (H) at position 7. This substitution
increases the net positive charge of the peptide from His (pKa ~6.0, imidazole-nitrogen) to Lys
(pKa ~ 10.5, ε-amino group), which might lead to enhancing antimicrobial activity given that it might
improve electrostatic attraction and interaction with negatively-charged bacterial cell surfaces as well
as conserving other structural parameters related to activity. The lysine substitution of histidine at
position 7 in the two novel phylloseptins, might also indicate an additional evolutionary adaptation
to aid the survival of these two species in a harsh environment [32]. To assess this prediction, we
further synthesised two modified analogues with lysine substituted by histidine at position 7 in both
peptides, naming these PS-Du K7H and PS-Co K7H, respectively. The synthetic K7H mutants of both
peptides showed decreased antimicrobial activity but similar haemolytic activities. Compared with
reported phylloseptins, these two novel phylloseptins exhibited more potent antimicrobial activities,
especially against the Gram positive bacterium, S. aureus, to nearly the lowest MIC value of 8 mg/L.
The anti-yeast activity of PS-Du and PS-Co with an MIC value of 16 mg/L, makes them the most
effective among most reported phylloseptins [14,16,19,34]. Both peptides showed less potent inhibition
of the Gram-negative bacterium E. coli (128 mg/L). As is known, Gram-negative bacteria have an
extra outer cellular membrane and a large proportion of highly negatively-charged lipopolysaccharide
(LPS) [35] making it more difficult for antimicrobial peptides to penetrate. Therefore, to disrupt
the cell membrane, higher concentrations of these two novel phylloseptins were required to induce
permeabilization of the inner membrane [34].
Meanwhile, both PS-Du and PS-Co exhibited potent anti-biofilm activity against a biofilm of
S. aureus. Biofilm, containing a polysaccharide matrix, is a special product of many microorganisms
for affording better protection and survival and can contribute to an increase in clinical infections
caused by its resistance to many antibiotics [36]. Nosocomial infections have become a serious problem
and 60% of these infections are associated with microorganism biofilm and most are Gram-positive
bacteria-related infections [37–39]. It is thus essential to discover new efficient anti-biofilm drugs to
treat biofilm-mediated infections. Antimicrobial peptides, which are natural defensive components of
the innate immune system against microorganisms, are attractive candidates showing great potential
in the treatment of bacterial biofilms [40–42]. Indeed, in previous studies, amphibian skin antimicrobial
peptides have been demonstrated to eradicate S. aureus biofilm [17,43,44]. In this study, both PS-Co
and PS-Du exhibited a potent action against S. aureus biofilm at a concentration of 16 mg/L, suggesting
that these two phylloseptins resist bacterial biofilm. However, it is unclear as to how they passed
through and disrupted the biofilm and thus further studies could combine cell staining and imaging
systems for anti-biofilm mechanism investigations.
Currently, the mechanism of bacterial inhibition by antimicrobial peptides has been
widely-accepted as non-specific membrane disruption, forming of toroidal pores and inducing damage
to intact cell membranes increasing their permeability [45,46]. The membrane permeabilization assay
employed here was a new approach to the study of the mechanism of these novel phylloseptins
in inhibiting the growth of microorganisms. The interaction of peptides with S. aureus bacterial
membranes was shown through cell membrane permeabilization enhancement with increasing peptide
concentrations. However, PS-Du and PS-Co did not fully permeabilize cell membranes at their MIC of
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8 mg/L. Regarding these lower concentrations of peptides, limited numbers or sizes of toroidal pores
might be formed.
In summary, two novel phylloseptin peptides, named PS-Du and PS-Co, were identified in the
skin secretion of Phyllomedusa duellmani and Phyllomedusa coelestis, respectively. Both peptides showed
potent antimicrobial activity against a Gram-positive bacterium and a yeast and both were able to
disrupt and eradicate S. aureus biofilm, in vitro. This study suggests that these phylloseptins may be
promising candidates in the discovery and development of new antibiotic drugs and also provided
new insights into natural antimicrobial drug design.
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